As yet it is unclear exactly how SIRT6 mono-ADP ribosylation promotes death in cancer cells, but it appears to be independent of PARP1, suggesting that there are additional targets for SIRT6-mediated mono-ADP ribosylation in vivo. The gene discussed is SIRT6; the disease is cancer.